|
|
 |
|
Viewing report
|
|
|
|
The Biotech Top 10
Centient Consulting, Inc, Oct 2005, Pages: 4
The The Biotech Investor™ has identified ten public biotechnology companies that it believes will outperform the market in 2006. This report identifies the companies 'most likely to succeed,' which run the gamut from companies with blockbuster drugs, strong earnings growth and solid pipelines, to highly speculative momentum plays full of promise but as yet unproven. In between, there are companies with drugs and drug candidates with significant potential, a beaten down stock ready to recover, and a built-in diversity plan. The one thing all of the top 10 biotechs have in common is that they are expected to do well over the next twelve months.
Reasons to Purchase
- Identify the ten public biotechs believed to hold significant promise in 2006
- Examine the scientific, market and political factors driving the potential success of these companies
- Identify potential investment opportunities in biotechnology
Target Audience
- Fund managers and individual investors seeking investments in biotech
- Analysts and journalists tracking the biotechnology market
- Others seeking to understand the driving factors and market dynamics
|
|
|
|
